Abstract
Protein tyrosine phosphatases (PTPs) are considered to be involved in the etiology of diabetes mellitus, neural diseases such as Alzheimers and Parkinsons disease, regulation of allergy and inflammation, or they are even considered to be responsible for the pathogens` virulence in vivo. Since discovery of first PTP inhibitors such as dephostatin in early 90th years, the research moved on toward search for inhibitors specific for the individual PTP molecules. Currently, dozens of new PTP inhibitors are reported each year, ranging from natural products, natural product analogs, peptides, phosphonates, nonpeptidic inhibitors, mimotopes, metalcontaining inhibitors, redox inhibitors, to simply silencing RNAs as widely used inhibitors of PTP expression. Several currently used drugs also show PTP inhibitory activity. Among them are sodium stibogluconate, phenylarsine oxide, alendronate, etidronate, vanadate, gallium nitrate, suramin, or aplidin. However, the market is still waiting for the first clinically approved selective PTP inhibitor. Here in this review are described inhibitors of activity or expression of the particular classical PTPs, with emphasis on specific inhibition of the respective PTP over the others. The inhibitors are not classified according to their chemical composition, but according to their biological activity, which should help to simplify search for inhibitors of particular classical PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.
Keywords: PTP1B, LAR, SHP-1, SHP-2, CD45, protein tyrosine phosphatase inhibition, cancer, diabetes mellitus
Current Medicinal Chemistry
Title: Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs
Volume: 16 Issue: 6
Author(s): P. Heneberg
Affiliation:
Keywords: PTP1B, LAR, SHP-1, SHP-2, CD45, protein tyrosine phosphatase inhibition, cancer, diabetes mellitus
Abstract: Protein tyrosine phosphatases (PTPs) are considered to be involved in the etiology of diabetes mellitus, neural diseases such as Alzheimers and Parkinsons disease, regulation of allergy and inflammation, or they are even considered to be responsible for the pathogens` virulence in vivo. Since discovery of first PTP inhibitors such as dephostatin in early 90th years, the research moved on toward search for inhibitors specific for the individual PTP molecules. Currently, dozens of new PTP inhibitors are reported each year, ranging from natural products, natural product analogs, peptides, phosphonates, nonpeptidic inhibitors, mimotopes, metalcontaining inhibitors, redox inhibitors, to simply silencing RNAs as widely used inhibitors of PTP expression. Several currently used drugs also show PTP inhibitory activity. Among them are sodium stibogluconate, phenylarsine oxide, alendronate, etidronate, vanadate, gallium nitrate, suramin, or aplidin. However, the market is still waiting for the first clinically approved selective PTP inhibitor. Here in this review are described inhibitors of activity or expression of the particular classical PTPs, with emphasis on specific inhibition of the respective PTP over the others. The inhibitors are not classified according to their chemical composition, but according to their biological activity, which should help to simplify search for inhibitors of particular classical PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.
Export Options
About this article
Cite this article as:
Heneberg P., Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs, Current Medicinal Chemistry 2009; 16 (6) . https://dx.doi.org/10.2174/092986709787458407
DOI https://dx.doi.org/10.2174/092986709787458407 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Antidiabetic Effect of Aqueous Corrigiola telephiifolia in Streptozotocin- Induced Diabetic Rats
The Natural Products Journal Growth Hormone/Insulin-Like Growth Factor-I Axis and Insulin in Alzheimers Disease and Its Possible Treatment Usefulness
Central Nervous System Agents in Medicinal Chemistry Effect of Alpha-1-Acid Glycoprotein Binding on Pharmacokinetics and Pharmacodynamics
Current Drug Metabolism Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Ovarian Granulosa Cell Tumor: A Clinicoradiologic Series with Literature Review
Current Medical Imaging Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery Interatrial Block in the Modern Era
Current Cardiology Reviews Methylation Profile of miR-9-1 and miR-9-1/-9-3 as Potential Biomarkers of Diabetic Retinopathy
Current Diabetes Reviews Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design <i>Cola Nitida</i> (Kola Nuts) Attenuates Hepatic Injury in Type 2 Diabetes by Improving Antioxidant and Cholinergic Dysfunctions and Dysregulated Lipid Metabolism
Endocrine, Metabolic & Immune Disorders - Drug Targets Glucocorticoid Measurements in Health and Disease - Metabolic Implications and the Potential of 24-h Urine Analyses
Mini-Reviews in Medicinal Chemistry Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Chalcones: As Potent α-amylase Enzyme Inhibitors; Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies
Medicinal Chemistry Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines
Current Molecular Medicine A Systematic Review of the Potential Herbal Sources of Future Drugs Effective in Oxidant-Related Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Iron-Induced Fibrin in Cardiovascular Disease
Current Neurovascular Research Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor
Current Drug Targets Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy